Related Experiment Videos
Minocycline in Huntington's disease: a pilot study
Madhavi Thomas1, Tetsuo Ashizawa, Joseph Jankovic
1Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas, USA. thomasmad@ninds.nih.gov
Summary
Minocycline showed good safety and tolerability in a 6-month study of Huntington's disease patients. This suggests potential for minocycline in managing Huntington's disease progression.
Area of Science:
- Neuroscience
- Pharmacology
- Clinical Trials
Background:
- Huntington's disease (HD) is a progressive neurodegenerative disorder.
- Minocycline, a tetracycline antibiotic, exhibits neuroprotective properties.
- Previous studies in mouse models suggest minocycline may delay HD progression.
Purpose of the Study:
- To evaluate the safety and tolerability of minocycline in patients with Huntington's disease.
- To assess the feasibility of a 6-month treatment regimen with minocycline.
Main Methods:
- A 6-month, open-label safety and tolerability study.
- Involved 30 patients diagnosed with Huntington's disease.
- Regular assessments included laboratory tests, clinical scales (AIMS, UHDRS), and cognitive tests (MMSE).
Main Results:
- Minocycline was well tolerated by all 30 participants over the 6-month study period.
- No serious adverse events were reported during the study.
- The study demonstrated the feasibility of administering minocycline to HD patients for 6 months.
Conclusions:
- Minocycline is a safe and well-tolerated medication for patients with Huntington's disease over a 6-month period.
- Further investigation into minocycline's efficacy for Huntington's disease is warranted based on these safety findings.